Header Logo

Connection

RUSSELL BROADDUS to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications RUSSELL BROADDUS has written about Aged, 80 and over.
RUSSELL BROADDUS
Connection Strength
0.600
Aged, 80 and over
  1. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019 03; 32(3):405-414.
    View in: PubMed
    Score: 0.039
  2. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol. 2019 03; 32(3):396-404.
    View in: PubMed
    Score: 0.039
  3. Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer. Cancer Prev Res (Phila). 2017 Feb; 10(2):108-115.
    View in: PubMed
    Score: 0.035
  4. Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma. Int J Gynecol Pathol. 2015 Nov; 34(6):497-506.
    View in: PubMed
    Score: 0.032
  5. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol. 2014 Aug; 134(2):319-25.
    View in: PubMed
    Score: 0.029
  6. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.029
  7. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.028
  8. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013 Oct; 26(10):1401-12.
    View in: PubMed
    Score: 0.027
  9. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012 Feb; 5(2):320-7.
    View in: PubMed
    Score: 0.024
  10. Molecular clustering based on ERa and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011 Mar; 24(3):453-62.
    View in: PubMed
    Score: 0.023
  11. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.012
  12. Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. Arch Pathol Lab Med. 2021 01 01; 145(1):46-54.
    View in: PubMed
    Score: 0.011
  13. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.011
  14. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.011
  15. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
    View in: PubMed
    Score: 0.011
  16. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Ann Oncol. 2019 06 01; 30(6):963-969.
    View in: PubMed
    Score: 0.010
  17. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.010
  18. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.010
  19. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.
    View in: PubMed
    Score: 0.010
  20. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol. 2018 01; 199(1):60-65.
    View in: PubMed
    Score: 0.009
  21. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
    View in: PubMed
    Score: 0.009
  22. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.009
  23. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
    View in: PubMed
    Score: 0.009
  24. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
    View in: PubMed
    Score: 0.009
  25. The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. Int J Gynecol Pathol. 2016 Jan; 35(1):16-24.
    View in: PubMed
    Score: 0.008
  26. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.008
  27. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.008
  28. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014 Oct-Dec; 207(10-12):495-502.
    View in: PubMed
    Score: 0.007
  29. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4.
    View in: PubMed
    Score: 0.007
  30. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.007
  31. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
    View in: PubMed
    Score: 0.007
  32. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
    View in: PubMed
    Score: 0.007
  33. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8.
    View in: PubMed
    Score: 0.007
  34. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov 06; 107(10):1776-82.
    View in: PubMed
    Score: 0.006
  35. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7(5):e36383.
    View in: PubMed
    Score: 0.006
  36. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar; 5(3):435-43.
    View in: PubMed
    Score: 0.006
  37. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.006
  38. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3570-6.
    View in: PubMed
    Score: 0.006
  39. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35.
    View in: PubMed
    Score: 0.005
  40. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.
    View in: PubMed
    Score: 0.005
  41. Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China. Int J Gynecol Cancer. 2009 May; 19(4):651-6.
    View in: PubMed
    Score: 0.005
  42. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009 Mar 26; 28(12):1496-505.
    View in: PubMed
    Score: 0.005
  43. Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2393-401.
    View in: PubMed
    Score: 0.005
  44. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008 Jul; 21(7):912-23.
    View in: PubMed
    Score: 0.005
  45. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.
    View in: PubMed
    Score: 0.005
  46. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20; 23(36):9344-50.
    View in: PubMed
    Score: 0.004
  47. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol. 2005 Apr; 166(4):1069-75.
    View in: PubMed
    Score: 0.004
  48. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
    View in: PubMed
    Score: 0.004
  49. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
    View in: PubMed
    Score: 0.004
  50. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004 Feb 10; 108(4):540-8.
    View in: PubMed
    Score: 0.004
  51. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.